Hypoimmune, Allogeneic CD22-Directed CAR T Cells That Evade Innate and Adaptive Immune Rejection for the Treatment of Large B Cell Lymphoma Patients That Are Relapsed/Refractory to CD19-Directed CAR T Cell TherapyAdam Johnson, Terry J. Fry, Chris Baldeviano et al.|Blood|2023Cited by 4
Development of a Novel, Allogeneic GPRC5D-Directed CAR for Treatment of Multiple Myeloma PatientsJeremy M. Kinder, Terry J. Fry, Chanel Athena Estrada et al.|Blood|2023Cited by 3
A Dual-Antigen Targeting, Hypoimmune Allogeneic CAR T to Evade Innate and Adaptive Immune Rejection and Overcome Antigen EscapeAdam Johnson, Aaron E. Foster, Hallee Wright et al.|Blood|2022Cited by 2
BCMA-Targeted, Hypoimmune Allogeneic CAR T Cells Exhibit Potent Anti-Tumor Activity Together with the Ability to Evade Innate and Adaptive Immune Rejection in Pre-Clinical Tumor ModelsJeremy M. Kinder, Aaron E. Foster, Chanel Athena-Estrada et al.|Blood|2022Cited by 1